Aprea Therapeutics, Inc. (APRE) Operating income 2021–2025
Aprea Therapeutics, Inc. (APRE) annual operating income history from SEC filings — each fiscal year as reported.
-$13.2MFY2025 · since FY2021: -$37.4M → -$13.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$13.2M | +7.6% |
| FY2024 | -$14.3M | +7.4% |
| FY2023 | -$15.5M | +86.4% |
| FY2022 | -$113.4M | -202.8% |
| FY2021 | -$37.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More APRE financial trends
APRE RevenueAPRE Net incomeAPRE Net marginAPRE Gross profitAPRE Gross marginAPRE Operating marginAPRE Operating cash flowAPRE Free cash flowAPRE Capital expendituresAPRE Return on equityAPRE Stock buybacksAPRE Dividends paidAPRE Total assetsAPRE Total liabilitiesAPRE Shareholders’ equityAPRE overview →